Biaxin XL

See also: Generic Biaxin

Biaxin XL is a brand name of clarithromycin, approved by the FDA in the following formulation(s):

BIAXIN XL (clarithromycin - tablet, extended release; oral)

• 
  Manufacturer: ABBOTT
  
  Approval date: March 3, 2000
  
  Strength(s): 500MG ^[RLD][AB]

Has a generic version of Biaxin XL been approved?

A generic version of Biaxin XL has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Biaxin XL and have been approved by the FDA:

clarithromycin tablet, extended release; oral

• 
  Manufacturer: SANDOZ
  
  Approval date: August 25, 2005
  
  Strength(s): 500MG ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: May 18, 2005
  
  Strength(s): 500MG ^[AB]


• 
  Manufacturer: WATSON LABS FLORIDA
  
  Approval date: June 24, 2004
  
  Strength(s): 500MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Biaxin XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Extended release formulations of erythromycin derivatives
  Patent 6,010,718
  Issued: January 4, 2000
  Inventor(s): Al-Razzak; Laman & Crampton; Sheri L. & Gustavson; Linda E. & Hui; Ho-Wah & Milman; Nelly & Semla; Susan J.
  Assignee(s): Abbott Laboratories
  Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower C.sub.max in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
  
  Patent expiration dates:
  
  
  • April 11, 2017
    
    ✓ 
    Patent use: TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS
    ✓ 
    Drug product
  
  



• 
  Extended release formulations of erythromycin derivatives
  Patent 6,551,616
  Issued: April 22, 2003
  Inventor(s): Gerard F.; Notario & Robert N.; Palmer & Richard C.; Hom & Jie; Zhang & Karen J.; Devcich & Susan J.; Semla
  Assignee(s): Abbott Laboratories
  Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
  
  Patent expiration dates:
  
  
  • July 15, 2017
    
    ✓ 
    Patent use: TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS
  
  

See also...

• Biaxin XL Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Biaxin XL Consumer Information (Cerner Multum)
• Biaxin XL-Pak Consumer Information (Cerner Multum)
• Biaxin XL Advanced Consumer Information (Micromedex)
• Clarithromycin Consumer Information (Drugs.com)
• Clarithromycin Consumer Information (Wolters Kluwer)
• Clarithromycin Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Clarithromycin Suspension Consumer Information (Wolters Kluwer)
• Clarithromycin Consumer Information (Cerner Multum)
• Clarithromycin Advanced Consumer Information (Micromedex)
• Clarithromycin AHFS DI Monographs (ASHP)